利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.021 秒)

    Treatment or prevention of anaemia in pregnant non-human mammals
    1.
    发明授权
    Treatment or prevention of anaemia in pregnant non-human mammals 有权

    公开(公告)号：US11040059B2

    公开(公告)日：2021-06-22

    申请号：US15522466

    申请日：2015-10-27

    申请人： Pharmacosmos Holding A/S

    发明人： Christian von der Recke ,  Tobias S. Christensen ,  Hans Andreasen ,  Lars Lykke Thomsen

    IPC分类号： A61K31/721 ,  A61K47/10 ,  A61K9/00 ,  A61K31/295

    摘要： The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

    Iron dextrin compounds for the treatment of iron deficiency anaemia
    2.
    发明申请
    Iron dextrin compounds for the treatment of iron deficiency anaemia 审中-公开
    铁糊精化合物用于治疗缺铁性贫血

    公开(公告)号：US20030191090A1

    公开(公告)日：2003-10-09

    申请号：US10408251

    申请日：2003-04-08

    申请人： PHARMACOSMOS HOLDING A/S

    发明人： Hans Berg Andreasen ,  Lars Christensen

    IPC分类号： C08B037/02 ,  A61K031/7024

    CPC分类号： C08B30/18 ,  A61K31/715 ,  A61K33/26 ,  A61K2300/00

    摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10% fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90% of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10% fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.

    摘要翻译： 一种用于治疗缺铁性贫血的铁糊精化合物，其包含与羟基氧化铝稳定结合的重均分子量等于或小于3,000道尔顿且数均分子量等于或高于400道尔顿的氢化糊精。 由于糊精的分子量必须窄，所以本发明的另一个重要特征是具有最高分子量的糊精的10％部分的平均分子量小于4500道尔顿，90％的糊精是 分子量小于3000道尔顿。 更重要的是具有最低分子量的10％馏分的重均分子量为340道尔顿或更高。

    STABLE IRON OLIGOSACCHARIDE COMPOUND
    5.
    发明申请
    STABLE IRON OLIGOSACCHARIDE COMPOUND 有权

    公开(公告)号：US20210130505A1

    公开(公告)日：2021-05-06

    申请号：US17142442

    申请日：2021-01-06

    申请人： PHARMACOSMOS HOLDING A/S

    发明人： Hans ANDREASEN

    IPC分类号： C08B37/02 ,  A61K47/26 ,  C07H3/06 ,  A61K31/721

    摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

    Stable iron oligosaccharide compound
    6.
    发明授权
    Stable iron oligosaccharide compound 有权

    公开(公告)号：US10414831B2

    公开(公告)日：2019-09-17

    申请号：US16178943

    申请日：2018-11-02

    申请人： Pharmacosmos Holding A/S

    发明人： Hans Andreasen

    IPC分类号： C08B37/02 ,  C07H3/06 ,  A61K31/721 ,  A61K47/26

    摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.